Why is Strides Pharma Science Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 5.10 times
- Poor long term growth as Net Sales has grown by an annual rate of 10.60% and Operating profit at 80.81% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 5.10 times
- The company has been able to generate a Return on Equity (avg) of 11.03% signifying low profitability per unit of shareholders funds
2
The company has declared Positive results for the last 13 consecutive quarters
- OPERATING CF(Y) Highest at Rs 702.52 Cr
- DEBT-EQUITY RATIO(HY) Lowest at 0.56 times
- DPR(Y) Highest at 8.29%
3
Technical trend is Sideways signifying no clear price momentum
- The technical trend has deteriorated from Mildly Bullish on 16-Nov-26 and has generated -2.14% returns since then
4
With ROCE of 14.3, it has a Very Attractive valuation with a 2.1 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 4.45%, its profits have risen by 31.7% ; the PEG ratio of the company is 0.5
How much should you hold?
- Overall Portfolio exposure to Strides Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Strides Pharma for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Strides Pharma
4.45%
0.11
39.33%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
10.60%
EBIT Growth (5y)
80.81%
EBIT to Interest (avg)
2.12
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
0.85
Tax Ratio
14.33%
Dividend Payout Ratio
8.29%
Pledged Shares
33.79%
Institutional Holding
43.50%
ROCE (avg)
8.83%
ROE (avg)
11.03%
Valuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
40
Price to Book Value
2.60
EV to EBIT
14.38
EV to EBITDA
11.11
EV to Capital Employed
2.05
EV to Sales
2.04
PEG Ratio
0.49
Dividend Yield
0.52%
ROCE (Latest)
14.28%
ROE (Latest)
16.81%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Technical Movement
8What is working for the Company
OPERATING CF(Y)
Highest at Rs 702.52 Cr
DEBT-EQUITY RATIO(HY)
Lowest at 0.56 times
DPR(Y)
Highest at 8.29%
NET SALES(Q)
Highest at Rs 1,429.73 cr
PBDIT(Q)
Highest at Rs 250.91 cr.
PBT LESS OI(Q)
Highest at Rs 148.06 cr.
-2What is not working for the Company
INTEREST(Q)
Highest at Rs 46.54 cr
Loading Valuation Snapshot...
Here's what is working for Strides Pharma
Debt-Equity Ratio - Half Yearly
Lowest at 0.56 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Cash Flow - Annually
Highest at Rs 702.52 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Net Sales - Quarterly
Highest at Rs 1,429.73 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 250.91 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 148.06 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Dividend Payout Ratio (DPR) - Annually
Highest at 8.29%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Here's what is not working for Strides Pharma
Interest - Quarterly
Highest at Rs 46.54 cr
in the last five quarters and Increased by 14.74 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)